German drugmaker Bayer (BAYN.ETR) said it is under investigation by the Chinese government as part of a deeper dig into a kickback scandal, The Wall Street Journal reported. A representative of China’s State Administration for Industry and Commerce visited a Bayer office in China at the end of last month, investigating a potential case of unfair competition, a Bayer spokeswoman said. The pharmaceutical industry is under scrutiny in China, where authorities in late June opened an investigation of GlaxoSmithKline (GSK.NYSE, GSK.LON), accusing the UK drug maker of bribing doctors and hospitals across China to boost drug sales.
Categories